Total, n | 39 |
---|---|
Female, n (%) | 11 (28.2) |
Age (years) | 63.23 ± 12.52 |
BMI (kg/m2) | 23.81 ± 3.70 |
Diatbetes, n (%) | 25 (64.1) |
Diabetic nephritis as primary disease, n (%) | 19 (48.7) |
Nephrosclerosis, n (%) | 5 (12.8) |
PD vintage (months) | 19.41 ± 21.73 |
D/P ratio | 0.687 ± 0.143 |
D/D0 ratio | 0.384 ± 0.106 |
Urinary volume (ml/day) | 899.2 ± 452.8 |
Dialysate dose (ml/day) | 5051.3 ± 1601.0 |
RASi, n (%) | 28 (71.8) |
Beta blocker, n (%) | 9 (23.1) |
Statin, n (%) | 15 (38.5) |
Diuretic (%) | 30 (76.9) |
Iron supplementation, n (%) | 9 (23.1) |
IVSd (mm) | 9.795 ± 2.166 |
PWd (mm) | 9.974 ± 2.194 |
LVDd (mm) | 48.54 ± 7.181 |
LVDs (mm) | 32.18 ± 7.904 |
LVMI (g/m2) | 120.7 ± 38.99 |
EF (%) | 61.62 ± 13.28 |
E/A | 0.747 ± 0.250 |
Cardiac index | 3.062 ± 1.334 |
Peritoneal Kt/V urea | 4.825 ± 1.679 |
Renal Kt/V urea | 3.816 ± 3.679 |
Weekly Kt/V urea | 1.711 ± 0.757 |
Peritoneal CCr (L/week/1.73 m2) | 3.623 ± 1.569 |
Renal CCr (L/week/1.73 m2) | 5.771 ± 5.690 |
Weekly CCr (L/week/1.73 m2) | 66.65 ± 34.43 |
Cr at starting PD (mg/dL) | 7.368 ± 2.893 |
eGFR at starting PD (mL/ min/1.73 m2) | 6.885 ± 2.293 |
ESA dose (μg/month) | 127.3 ± 78.46 |
Plasma erythropoietin (mIU/mL) | 7.933 ± 5.494 |
RBC (*104/μL) | 360.7 ± 43.23 |
Hb (g/dL) | 10.72 ± 1.266 |
Ht (%) | 32.76 ± 3.805 |
Reticulocyte (‰) | 10.33 ± 5.075 |
Fe (μg/dL) | 88.18 ± 30.58 |
TIBC (μg/dL) | 248.4 ± 41.77 |
Ferritin (ng/mL) | 158.9 ± 153.4 |
TSAT | 0.360 ± 0.133 |
CTR (%) | 49.57 ± 5.435 |
NT-proBNP (pg/mL) | 11839.8 ± 21293.2 |
Lactate (mg/dL) | 10.85 ± 5.386 |
Ca (mg/dL) | 8.438 ± 0.821 |
P (mg/dL) | 5.818 ± 1.612 |
iPTH (pg/mL) | 250.3 ± 117.4 |
Na (mEq/L) | 138.8 ± 3.639 |
K (mEq/L) | 4.564 ± 0.788 |
Cl (mEq/L) | 101.6 ± 4.951 |
BUN (mg/dL) | 62.20 ± 13.93 |
Cr (mg/dL) | 9.591 ± 3.438 |
TP (g/dL) | 6.241 ± 0.612 |
Alb (g/dL) | 3.269 ± 0.404 |
CRP (mg/dL) | 0.459 ± 2.144 |
sβ2MG (mg/L) | 24.43 ± 9.657 |
Venous pH | 7.360 ± 0.040 |
NYHA classification | |
 I, n (%) | 30 (76.9) |
 II, n (%) | 9 (23.1) |
 III and IV | None |